HOME ABOUT US PRINT PUBLICATIONS SUBSCRIPTIONS CONTACT US RSS
 
Welcome to FDAweb
Pay Per View
Search our 68,352 - story database FREE
 
Free Items
 Warning Letters
 FDA Notices
 FDA Calendar
 

 FDA Whistleblowers



    








 
     
 
Panel to Discuss NDA for Hypogonadism
08/20/2015
 

Federal Register Notice: FDA’s Bone, Reproductive, and Urologic Drugs Advisory Committee will meet 11/3, from 8:30 a.m. to 5 p.m. at FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (rm. 1503), Silver Spring, MD. The committee will discuss a Repros Therapeutics NDA, enclomiphene citrate 12.5 mg and 25 mg capsules for the proposed treatment of secondary hypogonadism in fertile men (men with more than 15 million sperm/ ml), younger than 60 years of age with a Body Mass Index (BMI) over 25 kg/meters squared. Contact Kalyani Bhatt, (301) 796-9001, email: BRUDAC@fda.hhs.gov. To view this notice, click here.

 
 
 
Any copying or electronic transfer without written permission is strictly prohibited and will result
in termination of service and prosecution under the federal Copyright Act.
To gain permission to copy this article log on to http://www.copyright.com.

FERDIC INCORPORATED - P.O. Box 28, Camp Hill, PA 17001 | Phone: (717)731-1426 fax:(717)731-1427 Email: info@fdaweb.com